Collectively, our findings illuminate the potential benefits of targeting PRMT6 as a therapeutic strategy to counteract both the STAT3 signaling pathway and the H3R2-mediated epigenetic mechanisms, offering new avenues for enhancing cancer treatment outcomes. Here, STAT3 is linked to cancer.